New drug trains immune system to eat cancer cells in early trial
NCT ID NCT07583914
First seen May 14, 2026 · Last updated May 21, 2026 · Updated 2 times
Summary
This early-phase trial tests a new drug that helps the immune system recognize and attack cancer cells by blocking a 'don't eat me' signal. It is for people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose in a small group of 9 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.